Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells

Developing cellular models of sporadic Alzheimer’s disease (sAD) is challenging due to the unknown initiator of disease onset and the slow disease progression that takes many years to develop in vivo. The use of human induced pluripotent stem cells (iPSCs) has revolutionised the opportunities to mod...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurochemical research 2018-12, Vol.43 (12), p.2179-2198
Hauptverfasser: Rowland, Helen A., Hooper, Nigel M., Kellett, Katherine A. B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2198
container_issue 12
container_start_page 2179
container_title Neurochemical research
container_volume 43
creator Rowland, Helen A.
Hooper, Nigel M.
Kellett, Katherine A. B.
description Developing cellular models of sporadic Alzheimer’s disease (sAD) is challenging due to the unknown initiator of disease onset and the slow disease progression that takes many years to develop in vivo. The use of human induced pluripotent stem cells (iPSCs) has revolutionised the opportunities to model AD pathology, investigate disease mechanisms and screen potential drugs. The majority of this work has, however, used cells derived from patients with familial AD (fAD) where specific genetic mutations drive disease onset. While these provide excellent models to investigate the downstream pathways involved in neuronal toxicity and ultimately neuronal death that leads to AD, they provide little insight into the causes and mechanisms driving the development of sAD. In this review we compare the data obtained from fAD and sAD iPSC-derived cell lines, identify the inconsistencies that exist in sAD models and highlight the potential role of Aβ clearance mechanisms, a relatively under-investigated area in iPSC-derived models, in the study of AD. We discuss the development of more physiologically relevant models using co-culture and three-dimensional culture of iPSC-derived neurons with glial cells. Finally, we evaluate whether we can develop better, more consistent models for sAD research using genetic stratification of iPSCs and identification of genetic and environmental risk factors that could be used to initiate disease onset for modelling sAD. These considerations provide exciting opportunities to develop more relevant iPSC models of sAD which can help drive our understanding of disease mechanisms and identify new therapeutic targets.
doi_str_mv 10.1007/s11064-018-2663-z
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6267251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2127844142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-895ad13fff47967d22916b528f251a3d91c24a6d9ce54ba6301a5cb4f17e1c03</originalsourceid><addsrcrecordid>eNp1UctKxDAUDaLo-PgAN1JwXb03SZN2I8j4GlAU1HXIJOlY6bRj0grOyt_w9_wSM4zPhau7OE_uIWQX4QAB5GFABMFTwDylQrB0vkIGmEmWigLYKhkAiyjDAjbIZgiPAFFFcZ1sMGC5BAkDcnXVWlfXVTNJbmet17YyyXE9f3DV1Pn317eQnFTB6eCS-7AgjRrbG2eTm7r31aztXNMlt52bJsPoErbJWqnr4HY-7xa5Ozu9G16kl9fno-HxZWq4hC7Ni0xbZGVZclkIaSktUIwzmpc0Q81sgYZyLWxhXMbHWjBAnZkxL1E6NMC2yNHSdtaPp86aWMLrWs18NdX-RbW6Un-RpnpQk_ZZCSpkjIgG-58Gvn3qXejUY9v7JlZWFKnMOUdOIwuXLOPbELwrvxMQ1GIAtRxAxQHUYgA1j5q939W-FV8fjwS6JIQINRPnf6L_d_0A3DWS9Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2127844142</pqid></control><display><type>article</type><title>Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rowland, Helen A. ; Hooper, Nigel M. ; Kellett, Katherine A. B.</creator><creatorcontrib>Rowland, Helen A. ; Hooper, Nigel M. ; Kellett, Katherine A. B.</creatorcontrib><description>Developing cellular models of sporadic Alzheimer’s disease (sAD) is challenging due to the unknown initiator of disease onset and the slow disease progression that takes many years to develop in vivo. The use of human induced pluripotent stem cells (iPSCs) has revolutionised the opportunities to model AD pathology, investigate disease mechanisms and screen potential drugs. The majority of this work has, however, used cells derived from patients with familial AD (fAD) where specific genetic mutations drive disease onset. While these provide excellent models to investigate the downstream pathways involved in neuronal toxicity and ultimately neuronal death that leads to AD, they provide little insight into the causes and mechanisms driving the development of sAD. In this review we compare the data obtained from fAD and sAD iPSC-derived cell lines, identify the inconsistencies that exist in sAD models and highlight the potential role of Aβ clearance mechanisms, a relatively under-investigated area in iPSC-derived models, in the study of AD. We discuss the development of more physiologically relevant models using co-culture and three-dimensional culture of iPSC-derived neurons with glial cells. Finally, we evaluate whether we can develop better, more consistent models for sAD research using genetic stratification of iPSCs and identification of genetic and environmental risk factors that could be used to initiate disease onset for modelling sAD. These considerations provide exciting opportunities to develop more relevant iPSC models of sAD which can help drive our understanding of disease mechanisms and identify new therapeutic targets.</description><identifier>ISSN: 0364-3190</identifier><identifier>EISSN: 1573-6903</identifier><identifier>DOI: 10.1007/s11064-018-2663-z</identifier><identifier>PMID: 30387070</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Alzheimer Disease - genetics ; Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Alzheimer's disease ; Amyloid beta-Peptides - genetics ; Amyloid beta-Peptides - metabolism ; Animals ; Biochemistry ; Biocompatibility ; Biomedical and Life Sciences ; Biomedicine ; Cell Biology ; Cell culture ; Cell Culture Techniques - methods ; Cell lines ; Cells, Cultured ; Coculture Techniques - methods ; Drug development ; Environmental risk ; Glial cells ; Humans ; Induced Pluripotent Stem Cells - pathology ; Induced Pluripotent Stem Cells - physiology ; Inhibitory postsynaptic potentials ; Modelling ; Mutation ; Neurochemistry ; Neurology ; Neuronal-glial interactions ; Neurosciences ; Neurotoxicity ; Overview ; Pluripotency ; Risk analysis ; Risk factors ; Stem cells ; Target recognition ; tau Proteins - genetics ; tau Proteins - metabolism ; Therapeutic applications ; Three dimensional models ; Toxicity</subject><ispartof>Neurochemical research, 2018-12, Vol.43 (12), p.2179-2198</ispartof><rights>The Author(s) 2018</rights><rights>Neurochemical Research is a copyright of Springer, (2018). All Rights Reserved. © 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-895ad13fff47967d22916b528f251a3d91c24a6d9ce54ba6301a5cb4f17e1c03</citedby><cites>FETCH-LOGICAL-c470t-895ad13fff47967d22916b528f251a3d91c24a6d9ce54ba6301a5cb4f17e1c03</cites><orcidid>0000-0002-2802-0615</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11064-018-2663-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11064-018-2663-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30387070$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rowland, Helen A.</creatorcontrib><creatorcontrib>Hooper, Nigel M.</creatorcontrib><creatorcontrib>Kellett, Katherine A. B.</creatorcontrib><title>Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells</title><title>Neurochemical research</title><addtitle>Neurochem Res</addtitle><addtitle>Neurochem Res</addtitle><description>Developing cellular models of sporadic Alzheimer’s disease (sAD) is challenging due to the unknown initiator of disease onset and the slow disease progression that takes many years to develop in vivo. The use of human induced pluripotent stem cells (iPSCs) has revolutionised the opportunities to model AD pathology, investigate disease mechanisms and screen potential drugs. The majority of this work has, however, used cells derived from patients with familial AD (fAD) where specific genetic mutations drive disease onset. While these provide excellent models to investigate the downstream pathways involved in neuronal toxicity and ultimately neuronal death that leads to AD, they provide little insight into the causes and mechanisms driving the development of sAD. In this review we compare the data obtained from fAD and sAD iPSC-derived cell lines, identify the inconsistencies that exist in sAD models and highlight the potential role of Aβ clearance mechanisms, a relatively under-investigated area in iPSC-derived models, in the study of AD. We discuss the development of more physiologically relevant models using co-culture and three-dimensional culture of iPSC-derived neurons with glial cells. Finally, we evaluate whether we can develop better, more consistent models for sAD research using genetic stratification of iPSCs and identification of genetic and environmental risk factors that could be used to initiate disease onset for modelling sAD. These considerations provide exciting opportunities to develop more relevant iPSC models of sAD which can help drive our understanding of disease mechanisms and identify new therapeutic targets.</description><subject>Alzheimer Disease - genetics</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer's disease</subject><subject>Amyloid beta-Peptides - genetics</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Animals</subject><subject>Biochemistry</subject><subject>Biocompatibility</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Biology</subject><subject>Cell culture</subject><subject>Cell Culture Techniques - methods</subject><subject>Cell lines</subject><subject>Cells, Cultured</subject><subject>Coculture Techniques - methods</subject><subject>Drug development</subject><subject>Environmental risk</subject><subject>Glial cells</subject><subject>Humans</subject><subject>Induced Pluripotent Stem Cells - pathology</subject><subject>Induced Pluripotent Stem Cells - physiology</subject><subject>Inhibitory postsynaptic potentials</subject><subject>Modelling</subject><subject>Mutation</subject><subject>Neurochemistry</subject><subject>Neurology</subject><subject>Neuronal-glial interactions</subject><subject>Neurosciences</subject><subject>Neurotoxicity</subject><subject>Overview</subject><subject>Pluripotency</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Stem cells</subject><subject>Target recognition</subject><subject>tau Proteins - genetics</subject><subject>tau Proteins - metabolism</subject><subject>Therapeutic applications</subject><subject>Three dimensional models</subject><subject>Toxicity</subject><issn>0364-3190</issn><issn>1573-6903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1UctKxDAUDaLo-PgAN1JwXb03SZN2I8j4GlAU1HXIJOlY6bRj0grOyt_w9_wSM4zPhau7OE_uIWQX4QAB5GFABMFTwDylQrB0vkIGmEmWigLYKhkAiyjDAjbIZgiPAFFFcZ1sMGC5BAkDcnXVWlfXVTNJbmet17YyyXE9f3DV1Pn317eQnFTB6eCS-7AgjRrbG2eTm7r31aztXNMlt52bJsPoErbJWqnr4HY-7xa5Ozu9G16kl9fno-HxZWq4hC7Ni0xbZGVZclkIaSktUIwzmpc0Q81sgYZyLWxhXMbHWjBAnZkxL1E6NMC2yNHSdtaPp86aWMLrWs18NdX-RbW6Un-RpnpQk_ZZCSpkjIgG-58Gvn3qXejUY9v7JlZWFKnMOUdOIwuXLOPbELwrvxMQ1GIAtRxAxQHUYgA1j5q939W-FV8fjwS6JIQINRPnf6L_d_0A3DWS9Q</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Rowland, Helen A.</creator><creator>Hooper, Nigel M.</creator><creator>Kellett, Katherine A. B.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2802-0615</orcidid></search><sort><creationdate>20181201</creationdate><title>Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells</title><author>Rowland, Helen A. ; Hooper, Nigel M. ; Kellett, Katherine A. B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-895ad13fff47967d22916b528f251a3d91c24a6d9ce54ba6301a5cb4f17e1c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Alzheimer Disease - genetics</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer's disease</topic><topic>Amyloid beta-Peptides - genetics</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Animals</topic><topic>Biochemistry</topic><topic>Biocompatibility</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Biology</topic><topic>Cell culture</topic><topic>Cell Culture Techniques - methods</topic><topic>Cell lines</topic><topic>Cells, Cultured</topic><topic>Coculture Techniques - methods</topic><topic>Drug development</topic><topic>Environmental risk</topic><topic>Glial cells</topic><topic>Humans</topic><topic>Induced Pluripotent Stem Cells - pathology</topic><topic>Induced Pluripotent Stem Cells - physiology</topic><topic>Inhibitory postsynaptic potentials</topic><topic>Modelling</topic><topic>Mutation</topic><topic>Neurochemistry</topic><topic>Neurology</topic><topic>Neuronal-glial interactions</topic><topic>Neurosciences</topic><topic>Neurotoxicity</topic><topic>Overview</topic><topic>Pluripotency</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Stem cells</topic><topic>Target recognition</topic><topic>tau Proteins - genetics</topic><topic>tau Proteins - metabolism</topic><topic>Therapeutic applications</topic><topic>Three dimensional models</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rowland, Helen A.</creatorcontrib><creatorcontrib>Hooper, Nigel M.</creatorcontrib><creatorcontrib>Kellett, Katherine A. B.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurochemical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rowland, Helen A.</au><au>Hooper, Nigel M.</au><au>Kellett, Katherine A. B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells</atitle><jtitle>Neurochemical research</jtitle><stitle>Neurochem Res</stitle><addtitle>Neurochem Res</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>43</volume><issue>12</issue><spage>2179</spage><epage>2198</epage><pages>2179-2198</pages><issn>0364-3190</issn><eissn>1573-6903</eissn><abstract>Developing cellular models of sporadic Alzheimer’s disease (sAD) is challenging due to the unknown initiator of disease onset and the slow disease progression that takes many years to develop in vivo. The use of human induced pluripotent stem cells (iPSCs) has revolutionised the opportunities to model AD pathology, investigate disease mechanisms and screen potential drugs. The majority of this work has, however, used cells derived from patients with familial AD (fAD) where specific genetic mutations drive disease onset. While these provide excellent models to investigate the downstream pathways involved in neuronal toxicity and ultimately neuronal death that leads to AD, they provide little insight into the causes and mechanisms driving the development of sAD. In this review we compare the data obtained from fAD and sAD iPSC-derived cell lines, identify the inconsistencies that exist in sAD models and highlight the potential role of Aβ clearance mechanisms, a relatively under-investigated area in iPSC-derived models, in the study of AD. We discuss the development of more physiologically relevant models using co-culture and three-dimensional culture of iPSC-derived neurons with glial cells. Finally, we evaluate whether we can develop better, more consistent models for sAD research using genetic stratification of iPSCs and identification of genetic and environmental risk factors that could be used to initiate disease onset for modelling sAD. These considerations provide exciting opportunities to develop more relevant iPSC models of sAD which can help drive our understanding of disease mechanisms and identify new therapeutic targets.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30387070</pmid><doi>10.1007/s11064-018-2663-z</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0002-2802-0615</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0364-3190
ispartof Neurochemical research, 2018-12, Vol.43 (12), p.2179-2198
issn 0364-3190
1573-6903
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6267251
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Alzheimer Disease - genetics
Alzheimer Disease - metabolism
Alzheimer Disease - pathology
Alzheimer's disease
Amyloid beta-Peptides - genetics
Amyloid beta-Peptides - metabolism
Animals
Biochemistry
Biocompatibility
Biomedical and Life Sciences
Biomedicine
Cell Biology
Cell culture
Cell Culture Techniques - methods
Cell lines
Cells, Cultured
Coculture Techniques - methods
Drug development
Environmental risk
Glial cells
Humans
Induced Pluripotent Stem Cells - pathology
Induced Pluripotent Stem Cells - physiology
Inhibitory postsynaptic potentials
Modelling
Mutation
Neurochemistry
Neurology
Neuronal-glial interactions
Neurosciences
Neurotoxicity
Overview
Pluripotency
Risk analysis
Risk factors
Stem cells
Target recognition
tau Proteins - genetics
tau Proteins - metabolism
Therapeutic applications
Three dimensional models
Toxicity
title Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T10%3A33%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modelling%20Sporadic%20Alzheimer%E2%80%99s%20Disease%20Using%20Induced%20Pluripotent%20Stem%20Cells&rft.jtitle=Neurochemical%20research&rft.au=Rowland,%20Helen%20A.&rft.date=2018-12-01&rft.volume=43&rft.issue=12&rft.spage=2179&rft.epage=2198&rft.pages=2179-2198&rft.issn=0364-3190&rft.eissn=1573-6903&rft_id=info:doi/10.1007/s11064-018-2663-z&rft_dat=%3Cproquest_pubme%3E2127844142%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2127844142&rft_id=info:pmid/30387070&rfr_iscdi=true